ASKA Licenses MHB018A for Japan in $440M Deal
Minghui Pharmaceutical grants ASKA Pharmaceutical exclusive Japanese rights to its subcutaneous IGF-1R antibody for thyroid eye disease.
Updated on Nov. 4, 2026 in Healthcare
Minghui Pharmaceutical has licensed MHB018A to ASKA Pharmaceutical for exclusive development and commercialization in Japan. The deal is worth up to $440 million plus royalties, with ASKA paying $110 million upfront.
Why it matters
The agreement lets Minghui pursue its global development strategy while a partner with local market expertise handles Japan. For readers in the international healthcare sector, it shows how biotech developers are using regional licensing to advance drugs for thyroid eye disease.
The deal carries up to $440 million plus royalties, with ASKA paying a $110 million upfront fee and more than 30% royalties on Japanese net sales. Phase 1/2 results showed proptosis reductions of 81% in active TED at 12 weeks and 76% in chronic TED at 24 weeks, but Japanese approval is still pending.
The players
Minghui Pharmaceutical
Minghui Pharmaceutical is a Chinese drugmaker that retains MHB018A rights outside Japan and continues its global development strategy for the candidate.
ASKA Pharmaceutical
ASKA Pharmaceutical is a Japanese drugmaker that holds a 96% share of the Japanese homegrown market, according to the company, and will commercialize MHB018A in Japan.
Guoqing Cao
Guoqing Cao is the chief executive of Minghui Pharmaceutical, who cited ASKA's market knowledge as a reason for the partnership.
The details
Minghui granted ASKA exclusive development and commercialization rights in Japan, and ASKA will handle the commercial rollout there. Minghui CEO Guoqing Cao cited ASKA's knowledge of the Japanese market and development pathway as reasons for choosing the partner.
Timeline
June: Phase 1/2 study results for MHB018A were released.
2024: Tepezza was approved in Japan.
November 4, 2026: ASKA's licensing deal with Minghui was announced.
Market Landscape
MHB018A targets the same IGF-1R pathway as Tepezza, which is already approved in Japan, but its subcutaneous delivery differs from Tepezza's intravenous administration. The licensing move positions ASKA to compete in a market where a Kissei-held rival, Lumvoa, has not yet been approved.
MHB018A's subcutaneous administration could make treatment for thyroid eye disease more convenient than intravenous options, though Japanese approval has not yet been granted. Patients in Japan will have to wait for regulatory approval before the drug can be prescribed there.
The takeaway
Licensing deals like this one let developers keep control of global strategy while local partners handle regulatory and commercial work in specific markets. For readers tracking thyroid eye disease treatments, subcutaneous options may become a growing alternative to intravenous therapies.
Further reading
Explore more Healthcare coverage for context on how drugmakers are structuring international licensing deals.
